Bipolar Disorder or Schizophrenia |
1.61 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CNNM2 FES PRMT7 |
Depressed Affect (Nagel 2018) |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTCH1 |
Intelligence (Savage-Jansen 2018) |
1.33 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
DCAF16 PLEKHA1 SND1 |
Neuroticism (Nagel 2018) |
1.26 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CNNM2 PTCH1 RP11-73O6.3 |
Schizophrenia (2018) |
1.55 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
C10orf26 CNNM2 FES |
Schizophrenia vs Biploar Disorder |
1.29 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CNNM2 |
Worry (Nagel 2018) |
1.42 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CNNM2 PTCH1 WDR78 |
Alzheimer’s Disease (including proxy) |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PLEKHA1 |
Crohns Disease (2017) |
1.73 |
4 |
1 |
2.2 |
0.56 |
4.4e-01 |
GPSM1 RFT1 RIT1 RPS9 |
Irritable Bowel Disease (IBD) |
1.84 |
5 |
1 |
2.2 |
0.30 |
6.3e-01 |
EIF2S2P3 GNA12 GPSM1 RIT1 TEAD3 |
Ulcerative Colitis (UC) |
1.81 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
GNA12 GPSM1 |
Major Depression (MDD) |
1.83 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CNNM2 FES |
Reaction Time |
1.84 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C17orf81 HECTD4 |
Verbal and Numeric Reasoning (VNR) |
1.27 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DCAF16 SND1 |
Breast Cancer |
1.79 |
6 |
1 |
2.2 |
-0.42 |
4.1e-01 |
C17orf81 FES LTBP3 PIK3R1 RIT1 RP11-73O6.3 |
Ovarian Cancer |
1.34 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRMT7 |
Prostate Cancer |
2.10 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM15 TNNT3 |
Body Mass Index (BMI) (2010) |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CNNM2 |
Coronary Artery Disease (CAD) |
2.32 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CNNM2 DCAF16 HECTD4 |
Crohns Disease (2012) |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RIT1 |
HbA1C |
1.62 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A |
HDL Cholesterol |
2.11 |
5 |
3 |
6.7 |
0.18 |
7.7e-01 |
ADRB1 BCL7B FBXL8 PRMT7 RFT1 |
LDL Cholesterol |
1.35 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
HECTD4 |
Lupus |
1.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Primary Biliary Cirrhosis |
1.34 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Rheumatoid Arthritis |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FCGR2B |
Schizophrenia (2014) |
1.72 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CNNM2 FES PRMT7 |
Triglycerides |
3.55 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
BCL7B |
Type 2 Diabetes (T2D) (2012) |
3.17 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ANK1 EIF2S2P3 PLEKHA1 |
Ulcerative Colitis |
1.65 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GNA12 GPSM1 |
Blood Eosinophil Count |
4.47 |
19 |
9 |
20.0 |
-0.41 |
7.7e-02 |
ADAM15 ADAM1A C17orf81 C6orf126 C6orf163 COMMD7 EIF2S2P3 FBXL8 GNA12 GPSM1 HECTD4 HSPB2 LTBP3 PIK3R1 RFT1 RP11-73O6.3 SESN1 TEAD3 XRN1 |
Blood Platelet Count |
2.78 |
17 |
11 |
24.4 |
-0.43 |
8.6e-02 |
ADAM15 ADAM1A BCL7B COMMD7 DCAF16 FCGR2B GNA12 HECTD4 LTBP3 ORAOV1 RAB14 RP11-864G5.3 SND1 STX16-NPEPL1 TIPARP TNNT3 WIT1 |
Blood Red Count |
1.84 |
18 |
11 |
24.4 |
-0.38 |
1.2e-01 |
ADAM15 ADAM1A CNNM2 EIF2S2P3 FCGR2B GNA12 GPR126 HECTD4 IGF2 ITPR2 PIK3R1 PRMT7 RP11-425D10.10 RP11-73O6.3 SESN1 STX16-NPEPL1 TEAD3 TIPARP |
Blood White Count |
3.14 |
23 |
15 |
33.3 |
-0.54 |
7.3e-03 |
ADAM1A BCL7B C6orf163 CCDC126 CNNM2 DCAF16 FCGR2B FES GNA12 GPSM1 HECTD4 HKDC1 ORAOV1 PLA2R1 PTCH1 RAB14 RFT1 RNPS1 RP11-73O6.3 RP11-864G5.3 TIPARP TRA2A WDR78 |
Heel T-Score |
3.01 |
18 |
13 |
28.9 |
-0.12 |
6.4e-01 |
ANAPC10 C17orf81 CNNM2 DCAF16 FBXL8 GNA12 GPR126 IGFBP3 KREMEN1 LOC100271722 RABGAP1 RFT1 RNPS1 RP11-173M1.8 RP11-73O6.3 SRR TIPARP XRN1 |
BMI |
1.28 |
12 |
6 |
13.3 |
0.59 |
4.5e-02 |
ADAM15 C17orf81 CNNM2 DCAF16 GPR126 HECTD4 KLHL24 LTBP3 ORAOV1 RIT1 RP11-73O6.3 SRR |
Height |
6.06 |
41 |
34 |
75.6 |
0.74 |
3.3e-08 |
ADAM15 ADRB1 ANAPC10 BCL7B C6orf126 CCDC126 COMMD7 DCAF16 FBXL8 FES GNA12 GPR126 GPSM1 HECTD4 HIF1AN HSPB2 IAH1 IGFBP3 KLHL24 KREMEN1 NUCKS1 PIK3R1 PLEKHA1 PTCH1 RABGAP1 RBMS1P1 RFT1 RNPS1 RP11-173M1.8 RP11-425D10.10 RP11-73O6.3 RP11-797D24.4 RP11-864G5.3 RPS9 SESN1 SRR TEAD3 TRA2A WDR78 XRN1 ZCCHC14 |
Waist Hip Ratio (WHR) |
3.31 |
15 |
11 |
24.4 |
-0.20 |
4.7e-01 |
ADAM15 ADAM1A ANAPC10 BCL7B C6orf126 EIF2S2P3 HSPB2 IAH1 IGFBP3 ORAOV1 PLA2R1 RFT1 RP11-73O6.3 TIPARP WIT1 |
Systolic Blood Pressure |
4.36 |
18 |
16 |
35.6 |
-0.40 |
1.0e-01 |
ADAM1A ADRB1 C10orf26 C17orf81 CNNM2 DCAF16 FES GPR126 HECTD4 HSPB2 PLEKHA1 PRKD3 RABGAP1 SND1 SRR TNNT3 UCKL1AS WIT1 |
Smoking Status |
1.23 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAM1A FES SRR |
Allergy or Eczema |
2.09 |
10 |
3 |
6.7 |
-0.13 |
7.1e-01 |
ADAM15 ADAM1A FES GNA12 HECTD4 HSPB2 RIT1 SESN1 SRR WDR78 |
Cardiovascular Disease |
3.31 |
13 |
9 |
20.0 |
-0.46 |
1.1e-01 |
ADAM1A ADRB1 C17orf81 CNNM2 COG5 DCAF16 FES HECTD4 HSPB2 KREMEN1 NUCKS1 TNNT3 UCKL1AS |
Hypothyroidism (self reported) |
3.66 |
6 |
4 |
8.9 |
-0.33 |
5.2e-01 |
ADAM1A C6orf163 HECTD4 PLEKHA1 PRMT7 SESN1 |
Respiratory disease |
1.70 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF2S2P3 HSPB2 |
Type 2 Diabetes (T2D) (2018) |
3.12 |
4 |
2 |
4.4 |
-0.46 |
5.4e-01 |
ADAM1A ANK1 EIF2S2P3 GPSM1 |
Lung FEV1/FVC ratio |
4.78 |
12 |
7 |
15.6 |
-0.30 |
3.5e-01 |
ADAM15 DTWD1 FBXL8 FCGR2B GNA12 GPR126 NUCKS1 PLA2R1 PRMT7 PTCH1 RP11-173M1.8 SESN1 |
Lung FVC |
1.79 |
13 |
6 |
13.3 |
0.16 |
6.0e-01 |
ANAPC10 C17orf81 C6orf126 C6orf163 CCDC126 DCAF16 GPSM1 HECTD4 HKDC1 NUCKS1 PTCH1 TEAD3 TIPARP |
Neuroticism |
1.24 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CNNM2 PTCH1 |
Chronotype (morning person) |
0.94 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf26 GPSM1 HECTD4 |
Hair Pigment |
0.24 |
6 |
6 |
13.3 |
-0.12 |
8.2e-01 |
C11orf21 FES HECTD4 NUCKS1 RIT1 RP11-73O6.3 |
Tanning |
0.33 |
4 |
1 |
2.2 |
-0.93 |
6.7e-02 |
ADAM15 DTWD1 HECTD4 IGFBP3 |
Hand grip strength (left) |
2.49 |
7 |
3 |
6.7 |
0.90 |
5.1e-03 |
DCAF16 FES NUCKS1 RFT1 RP11-73O6.3 SND1 TRA2A |
Number of treatments/medications taken |
1.95 |
4 |
0 |
0.0 |
-1.00 |
4.8e-03 |
ADAM1A DCAF16 HECTD4 NUCKS1 |
Sensitivity / hurt feelings |
1.34 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PTCH1 |
Hearing difficulty/problems: Yes |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C17orf81 |
Systolic blood pressure, automated reading |
3.20 |
11 |
6 |
13.3 |
-0.36 |
2.8e-01 |
ADRB1 C10orf26 C17orf81 CNNM2 DCAF16 FES HECTD4 HSPB2 PRKD3 SRR TNNT3 |
Angina |
1.59 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Medication: Metformin |
2.11 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF2S2P3 |
Diabetes (father) |
2.30 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF2S2P3 |
Diabetes (mother) |
1.90 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ANK1 EIF2S2P3 RP11-797D24.4 |
Pack years adult smoking proportion |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RFT1 |
Impedance of leg (right) |
2.46 |
12 |
9 |
20.0 |
-0.85 |
5.2e-04 |
ADAM15 C6orf163 CNNM2 FES GPR126 IGFBP3 LTBP3 ORAOV1 PTCH1 RIT1 RP11-73O6.3 SRR |
Leg fat-free mass (left) |
4.63 |
27 |
20 |
44.4 |
0.94 |
3.3e-13 |
ADAM15 ANAPC10 C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 FES GNA12 GPR126 HECTD4 HIF1AN IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TRA2A XRN1 |
Trunk fat percentage |
1.33 |
7 |
3 |
6.7 |
0.44 |
3.2e-01 |
C6orf126 GNA12 GPR126 KLHL24 PLEKHA1 SRR TEAD3 |
Hand grip strength (right) |
2.62 |
8 |
4 |
8.9 |
0.73 |
4.2e-02 |
DCAF16 IGFBP3 NUCKS1 PTCH1 RFT1 RP11-73O6.3 TRA2A UCKL1AS |
Fed-up feelings |
1.24 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C17orf81 HECTD4 |
Relative age voice broke |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A |
Taking other prescription medications |
1.55 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A HECTD4 |
Age when periods started (menarche) |
1.12 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RFT1 TIPARP |
Heel bone mineral density (BMD) T-score, automated (left) |
1.74 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
FBXL8 KREMEN1 TIPARP |
High blood pressure |
3.55 |
14 |
8 |
17.8 |
-0.49 |
7.9e-02 |
ADAM1A ADRB1 C17orf81 CNNM2 DCAF16 FES HECTD4 HSPB2 KREMEN1 NUCKS1 SRR TNNT3 UCKL1AS WIT1 |
Hayfever, allergic rhinitis or eczema |
1.96 |
5 |
1 |
2.2 |
-0.36 |
5.5e-01 |
ADAM15 ADAM1A HSPB2 RAB14 WDR78 |
Medication: Atenolol |
2.51 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FES HECTD4 |
Medication: Levothyroxine sodium |
2.94 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ADAM1A HECTD4 PLEKHA1 |
Sitting height |
6.96 |
29 |
23 |
51.1 |
0.67 |
7.4e-05 |
ADAM15 ADRB1 ANAPC10 C6orf163 CCDC126 COMMD7 DCAF16 FBXL8 GNA12 GPR126 GPSM1 HIF1AN IGFBP3 ITPR2 KREMEN1 NUCKS1 PIK3R1 PTCH1 RBMS1P1 RFT1 RP11-425D10.10 RP11-73O6.3 RP11-797D24.4 TEAD3 TIPARP TRA2A WDR78 XRN1 ZCCHC14 |
High blood pressure (mother) |
2.33 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ADRB1 CNNM2 FES |
Body mass index (BMI) |
1.27 |
9 |
3 |
6.7 |
0.43 |
2.5e-01 |
ADAM15 CNNM2 DCAF16 KLHL24 LTBP3 ORAOV1 RFT1 RP11-73O6.3 SRR |
Impedance of leg (left) |
2.45 |
12 |
9 |
20.0 |
-0.83 |
8.3e-04 |
ADAM15 C6orf163 CNNM2 FES GPR126 IGFBP3 LTBP3 ORAOV1 PTCH1 RIT1 RP11-73O6.3 SRR |
Leg predicted mass (left) |
4.60 |
26 |
20 |
44.4 |
0.94 |
6.9e-13 |
ADAM15 ANAPC10 C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 FES GNA12 GPR126 HECTD4 HIF1AN IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TRA2A |
Trunk fat mass |
1.83 |
9 |
6 |
13.3 |
0.99 |
4.3e-07 |
ANAPC10 CNNM2 GNA12 GPR126 KLHL24 PLEKHA1 RNPS1 RP11-73O6.3 SRR |
Waist circumference |
1.52 |
6 |
2 |
4.4 |
0.84 |
3.5e-02 |
ADAM15 C17orf81 GNA12 PLEKHA1 RNPS1 TIPARP |
Number of incorrect matches in round |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PLEKHA1 |
Past tobacco smoking |
1.22 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A SRR |
Nervous feelings |
1.30 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CNNM2 |
Frequency of tenseness / restlessness in last 2 weeks |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CNNM2 |
Hearing difficulty/problems with background noise |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUCKS1 |
Forced vital capacity (FVC) |
4.16 |
13 |
9 |
20.0 |
0.97 |
7.4e-08 |
ANAPC10 C6orf126 CCDC126 DCAF16 GNA12 GPR126 IGFBP3 PTCH1 RFT1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A |
Heel bone mineral density (BMD) T-score, automated (right) |
1.87 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
FBXL8 KREMEN1 TIPARP |
Heart attack |
1.80 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Allergy |
1.87 |
6 |
1 |
2.2 |
-0.28 |
5.9e-01 |
ADAM1A FES GNA12 HSPB2 SESN1 WDR78 |
Diabetes (self-reported) |
2.56 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ANK1 EIF2S2P3 GPSM1 |
Medication: Ramipril |
1.82 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A FES |
Medication: Simvastatin |
1.83 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DCAF16 FES |
Fluid intelligence score |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Illnesses of siblings |
1.84 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A FES HECTD4 |
Neuroticism score |
0.99 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PTCH1 |
Weight |
3.18 |
19 |
12 |
26.7 |
0.95 |
5.4e-10 |
ADAM15 ANAPC10 CCDC126 CNNM2 DCAF16 GNA12 GPR126 HECTD4 HIF1AN KLHL24 LTBP3 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RNPS1 RP11-73O6.3 TRA2A |
Impedance of arm (right) |
1.92 |
10 |
5 |
11.1 |
0.09 |
8.0e-01 |
ADAM15 GPR126 IGFBP3 KREMEN1 LTBP3 RP11-73O6.3 RP11-864G5.3 TIPARP UCKL1AS WIT1 |
Arm fat percentage (right) |
1.42 |
8 |
4 |
8.9 |
-0.46 |
2.5e-01 |
CNNM2 DCAF16 KLHL24 LTBP3 ORAOV1 RABGAP1 SRR TEAD3 |
Trunk fat-free mass |
5.49 |
29 |
20 |
44.4 |
0.91 |
5.9e-12 |
ADAM15 ANAPC10 BCL7B C6orf126 C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A WDR78 |
Hip circumference |
2.79 |
14 |
10 |
22.2 |
0.94 |
5.0e-07 |
ADAM15 ANAPC10 BCL7B C17orf81 CNNM2 GNA12 GPR126 HECTD4 KLHL24 ORAOV1 PLEKHA1 PTCH1 RNPS1 RP11-73O6.3 |
Father's age at death |
1.53 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES HECTD4 |
Worrier / anxious feelings |
1.33 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CNNM2 PTCH1 SND1 |
Forced expiratory volume in 1-second (FEV1) |
3.04 |
11 |
6 |
13.3 |
0.97 |
1.6e-06 |
ANAPC10 C6orf126 CCDC126 DCAF16 IGFBP3 PTCH1 RFT1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A |
Qualifications: A levels/AS levels or equivalent |
0.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Asthma |
1.70 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 HSPB2 |
Medication: Ibuprofen (e.g. Nurofen) |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Medication: Cholesterol lowering |
1.74 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DCAF16 FES |
Illnesses of mother |
1.86 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Forced expiratory volume in 1-second (FEV1), Best measure |
3.09 |
10 |
6 |
13.3 |
0.97 |
4.0e-06 |
ANAPC10 C6orf126 CCDC126 DCAF16 IGFBP3 PLA2R1 RFT1 RP11-73O6.3 TEAD3 TRA2A |
Pulse wave Arterial Stiffness index |
1.91 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAM1A |
Impedance of arm (left) |
1.86 |
12 |
3 |
6.7 |
0.06 |
8.5e-01 |
ADAM15 GNA12 GPR126 HECTD4 KREMEN1 LTBP3 ORAOV1 RP11-73O6.3 RP11-864G5.3 TIPARP UCKL1AS WIT1 |
Arm fat mass (right) |
1.59 |
10 |
4 |
8.9 |
1.00 |
2.6e-10 |
ADAM15 CNNM2 GNA12 KLHL24 LTBP3 ORAOV1 PLEKHA1 RNPS1 RP11-73O6.3 SRR |
Trunk predicted mass |
5.51 |
29 |
21 |
46.7 |
0.91 |
5.8e-12 |
ADAM15 ANAPC10 BCL7B C6orf126 C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A WDR78 |
Standing height |
5.96 |
30 |
27 |
60.0 |
0.80 |
1.0e-07 |
ADAM15 ADRB1 ANAPC10 C6orf126 CCDC126 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 NUCKS1 PIK3R1 PLEKHA1 PTCH1 RABGAP1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 RP11-797D24.4 TEAD3 TRA2A WDR78 XRN1 ZCCHC14 |
Tense / 'highly strung' |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CNNM2 |
Hair/balding pattern: Pattern 4 |
1.15 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SRR |
Birth weight of first child |
6.91 |
23 |
9 |
20.0 |
0.93 |
6.7e-11 |
ADAM15 ADAM1A ANAPC10 C10orf26 C17orf81 C6orf126 DCAF16 FES HECTD4 HKDC1 IAH1 IGFBP3 ITPR2 PIK3R1 PLEKHA1 RP11-797D24.4 RP11-864G5.3 RPS9 SESN1 SND1 TEAD3 TIPARP WIT1 |
Peak expiratory flow (PEF) |
2.08 |
4 |
3 |
6.7 |
0.99 |
1.5e-02 |
ANAPC10 DCAF16 NUCKS1 RP11-425D10.10 |
Qualifications: O levels/GCSEs or equivalent |
0.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUCKS1 |
Mouth/teeth dental problems: Bleeding gums |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SND1 |
Medication for cholesterol, blood pressure or diabetes |
2.57 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
DCAF16 FES HSPB2 |
Gout (self-reported) |
1.38 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM15 HECTD4 |
Hypothyroidism/myxoedema (self-reported) |
3.13 |
6 |
2 |
4.4 |
-0.31 |
5.5e-01 |
ADAM1A C6orf163 HECTD4 PLEKHA1 PRMT7 SESN1 |
Medication: Amlodipine |
1.79 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES TNNT3 |
High blood pressure (siblings) |
1.95 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES HECTD4 |
Forced vital capacity (FVC), Best measure |
4.13 |
13 |
10 |
22.2 |
0.97 |
5.5e-08 |
ANAPC10 C11orf21 C6orf126 CCDC126 DCAF16 GNA12 GPR126 IGFBP3 PTCH1 RFT1 RP11-73O6.3 TEAD3 TRA2A |
Body fat percentage |
1.21 |
5 |
1 |
2.2 |
-0.58 |
3.0e-01 |
C6orf126 DCAF16 KLHL24 SRR TEAD3 |
Leg fat percentage (right) |
1.26 |
4 |
2 |
4.4 |
-0.64 |
3.6e-01 |
DCAF16 IGFBP3 LTBP3 TEAD3 |
Arm fat-free mass (right) |
4.79 |
28 |
18 |
40.0 |
0.89 |
2.7e-10 |
ADAM15 ANAPC10 BCL7B C11orf21 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 IAH1 IGFBP3 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 RP11-864G5.3 TEAD3 TRA2A |
Comparative body size at age 10 |
2.01 |
8 |
3 |
6.7 |
0.96 |
1.5e-04 |
HKDC1 KLHL24 LTBP3 ORAOV1 PLA2R1 RIT1 SRR WDR78 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.44 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADRB1 |
Wheeze or whistling in the chest in last year |
1.69 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
HSPB2 XRN1 |
Age at first live birth |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Pulse wave peak to peak time |
1.77 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAM1A |
Qualifications: College or University degree |
1.11 |
4 |
2 |
4.4 |
-0.01 |
9.9e-01 |
C6orf163 DCAF16 RP11-864G5.3 SND1 |
Medication: Blood pressure |
3.04 |
9 |
2 |
4.4 |
-0.42 |
2.6e-01 |
ADAM1A ADRB1 C17orf81 DCAF16 FES HECTD4 HSPB2 TNNT3 WIT1 |
Angina (self-reported) |
1.58 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Medication: Allopurinol |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM15 |
Medication: Seretide 50 evohaler |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRMT7 |
Mean time to correctly identify matches |
2.02 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
C17orf81 HECTD4 RP11-73O6.3 |
Whole body fat mass |
1.65 |
11 |
3 |
6.7 |
0.98 |
1.1e-07 |
ADAM15 ANAPC10 CNNM2 GNA12 GPR126 KLHL24 LTBP3 PLEKHA1 RNPS1 RP11-73O6.3 SRR |
Leg fat mass (right) |
1.35 |
7 |
2 |
4.4 |
0.99 |
1.5e-05 |
ADAM15 CNNM2 GNA12 HECTD4 KLHL24 LTBP3 RP11-73O6.3 |
Arm predicted mass (right) |
4.82 |
27 |
18 |
40.0 |
0.90 |
2.8e-10 |
ADAM15 ANAPC10 BCL7B C11orf21 CCDC126 CNNM2 DCAF16 GNA12 GPR126 GPSM1 HECTD4 IAH1 IGFBP3 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 RP11-864G5.3 TEAD3 TRA2A |
Pulse rate, automated reading |
1.25 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RFT1 RP11-864G5.3 |
Comparative height size at age 10 |
5.22 |
26 |
19 |
42.2 |
0.90 |
2.2e-10 |
ADAM15 ANAPC10 C6orf126 CCDC126 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HKDC1 IAH1 IGFBP3 KLHL24 NUCKS1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A WDR78 |
Overall health rating |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRA2A |
Age at last live birth |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 |
Family relationship satisfaction |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP11-73O6.3 |
Medication: Aspirin |
1.95 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Hypertension (Self-reported) |
3.48 |
14 |
7 |
15.6 |
-0.49 |
7.6e-02 |
ADAM1A ADRB1 C17orf81 CNNM2 DCAF16 FES HECTD4 HSPB2 KREMEN1 NUCKS1 SRR TNNT3 UCKL1AS WIT1 |
Illnesses of father: Heart disease |
1.71 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Illnesses of siblings: Diabetes |
1.77 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 |
Smoking status: Previous |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Forced expiratory volume in 1-second (FEV1), predicted |
4.47 |
11 |
6 |
13.3 |
0.96 |
1.7e-06 |
ANAPC10 COMMD7 DCAF16 GNA12 GPR126 GPSM1 PTCH1 RFT1 RP11-73O6.3 TEAD3 TRA2A |
Whole body fat-free mass |
5.22 |
30 |
22 |
48.9 |
0.91 |
4.0e-12 |
ADAM15 ANAPC10 BCL7B C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A WDR78 |
Leg fat-free mass (right) |
4.71 |
29 |
19 |
42.2 |
0.93 |
1.7e-13 |
ADAM15 ANAPC10 BCL7B C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 FES GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TRA2A |
Arm fat percentage (left) |
1.37 |
7 |
4 |
8.9 |
0.07 |
8.8e-01 |
CNNM2 DCAF16 KLHL24 LTBP3 PLEKHA1 SRR TEAD3 |
Diabetes diagnosed by doctor |
2.66 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ANK1 EIF2S2P3 GPSM1 |
Mouth/teeth dental problems: Mouth ulcers |
1.00 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
DTWD1 STX16-NPEPL1 |
Medication for cholesterol |
2.30 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES HECTD4 |
Asthma (self-reported) |
1.65 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 HSPB2 |
Osteoarthritis (self-reported) |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUCKS1 |
Medication: Aspirin |
2.04 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Illnesses of father: None of the above (group 1) |
2.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GPR126 |
Whole body water mass |
5.20 |
29 |
22 |
48.9 |
0.93 |
1.8e-13 |
ADAM15 ANAPC10 BCL7B C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A |
Leg predicted mass (right) |
4.72 |
29 |
18 |
40.0 |
0.93 |
1.7e-13 |
ADAM15 ANAPC10 BCL7B C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 FES GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TRA2A |
Arm fat mass (left) |
1.56 |
10 |
4 |
8.9 |
1.00 |
2.5e-10 |
ADAM15 CNNM2 GNA12 KLHL24 LTBP3 ORAOV1 PLEKHA1 RNPS1 RP11-73O6.3 SRR |
Number of self-reported non-cancer illnesses |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Guilty feelings |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTCH1 |
Medication: Blood pressure |
2.98 |
7 |
5 |
11.1 |
-0.68 |
9.6e-02 |
ADRB1 CNNM2 FES HECTD4 HSPB2 TNNT3 UCKL1AS |
High cholesterol (Self-reported) |
1.25 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Medication: Bendroflumethiazide |
1.94 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADRB1 FES TNNT3 |
Illnesses of father: High blood pressure |
1.88 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Ever smoked |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SRR |
Basal metabolic rate |
4.81 |
29 |
19 |
42.2 |
0.93 |
2.2e-13 |
ADAM15 ANAPC10 BCL7B C6orf163 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 KLHL24 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 TEAD3 TRA2A |
Leg fat percentage (left) |
1.23 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
DCAF16 LTBP3 TEAD3 |
Arm fat-free mass (left) |
4.64 |
28 |
17 |
37.8 |
0.89 |
1.9e-10 |
ADAM15 ANAPC10 C11orf21 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 RP11-864G5.3 TEAD3 TRA2A |
Number of operations (self-reported) |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CCDC126 |
Irritability |
1.29 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP11-73O6.3 |
Fractured/broken bones in last 5 years |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PLEKHA1 |
Diastolic blood pressure, automated reading |
2.79 |
8 |
7 |
15.6 |
-0.27 |
5.2e-01 |
ADAM1A ADRB1 C17orf81 CNNM2 DCAF16 FES HECTD4 SRR |
Vascular/heart problems diagnosed by doctor |
3.66 |
13 |
8 |
17.8 |
0.68 |
1.0e-02 |
ADAM1A ADRB1 CNNM2 DCAF16 FES HECTD4 HSPB2 KREMEN1 NUCKS1 SRR TEAD3 TNNT3 UCKL1AS |
Cholesterol lowering medication |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Pain experienced in last month |
0.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Heart attack/myocardial infarction (self-reported) |
1.85 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Heart disease (siblings) |
1.34 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Impedance of whole body |
2.11 |
12 |
7 |
15.6 |
-0.60 |
4.1e-02 |
ADAM15 ADAM1A C6orf163 CNNM2 GPR126 IGFBP3 KREMEN1 LTBP3 ORAOV1 PTCH1 RP11-73O6.3 WIT1 |
Leg fat mass (left) |
1.38 |
7 |
2 |
4.4 |
0.99 |
1.7e-05 |
ADAM15 CNNM2 GNA12 HECTD4 KLHL24 LTBP3 RP11-73O6.3 |
Arm predicted mass (left) |
4.60 |
27 |
16 |
35.6 |
0.89 |
4.6e-10 |
ADAM15 ANAPC10 CCDC126 CNNM2 COMMD7 DCAF16 GNA12 GPR126 GPSM1 HECTD4 HIF1AN IAH1 IGFBP3 LTBP3 NUCKS1 ORAOV1 PIK3R1 PLEKHA1 PTCH1 RBMS1P1 RFT1 RNPS1 RP11-425D10.10 RP11-73O6.3 RP11-864G5.3 TEAD3 TRA2A |